CA-4948

DRUG6 trials

Sponsors

Curis Inc., University of Leipzig, Washington University School of Medicine, University of Florida

Conditions

Acute Myelogenous Leukemia (AML) or higher-risk Myelodysplastic Syndrome (MDS).AnemiaChronic Lymphocytic Leukemia and Other B-cell MalignanciesEsophageal CancerEsophagus CancerGastric CancerGastroesophageal Junction CancerMelanoma Metastatic in the Brain

Phase 1

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

RecruitingNCT05187182

Washington University School of MedicineEsophageal Cancer, Esophagus Cancer, Gastric Cancer +2

Start: 2023-06-02End: 2028-06-30Target: 42Updated: 2026-03-18

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

SuspendedNCT05669352

University of FloridaMelanoma Metastatic in the Brain

Start: 2025-04-30End: 2027-08-31Target: 29Updated: 2025-04-04

An Open-Label, Dose Escalation and Dose Expansion Trial Evaluating the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered CA-4948 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma

RecruitingCTIS2024-513312-95-00

Curis Inc.Part A2. Relapsed or Refractory Hematologic Malignancy. (Enrolment is closed), Part B+C. Primary central nervous system lymphoma (PCNSL)

Start: 2023-05-30Target: 69Updated: 2025-09-25

A Phase 1/2A, Open Label Dose Escalation and Cohort Expansion Study of Orally Administered CA-4948 (IRAK4i) as a Monotherapy in Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

CompletedCTIS2024-513313-13-00

Curis Inc.Acute Myelogenous Leukemia (AML) or higher-risk Myelodysplastic Syndrome (MDS).

Start: 2020-12-09End: 2025-02-26Target: 70Updated: 2024-09-30

Phase 2

Treatment of Anemia in Patients With Very Low, Low or Intermediate Risk Myelodysplastic Syndromes With CA-4948

TerminatedNCT05178342

University of LeipzigAnemia, Myelodysplastic Syndromes

Start: 2022-01-01End: 2024-07-31Updated: 2024-08-13

A Phase 2 Study of Emavusertib in Combination with an Approved Bruton Tyrosine Kinase Inhibitor in Patients with Chronic Lymphocytic Leukemia and Other B-cell Malignancies

Not yet recruitingCTIS2025-523600-68-00

Curis Inc.Chronic Lymphocytic Leukemia and Other B-cell Malignancies

Target: 40Updated: 2026-03-16

Related Papers

Phase I trial of emavusertib (CA-4948) in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated, unresectable gastric and esophageal cancer.

Journal of Clinical Oncology2026-01-10

EXTH-119. Targeting myddosome signaling to improve immunotherapy in melanoma brain metastases

Neuro-Oncology2025-11-01

Phase I trial of CA-4948, an IRAK4 inhibitor, in combination with FOLFOX/PD-1 inhibitor +/- trastuzumab for untreated unresectable gastric and esophageal cancer.

Journal of Clinical Oncology2022-06-013 citations